Skip to main content

Advertisement

Table 2 Number (%) of participants with composite adverse events and treatment differences

From: Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Composite adverse event Number (%) Treatment difference (95% CI)
12 mg (N = 652) 40 mg (N = 652) Placebo (N = 653) 12 mg vs. placebo 40 mg vs. placebo
Delirium-like events 13 (2.0) 31 (4.8) 22 (3.4) − 1.38 (− 3.26, 0.40) 1.39 (− 0.78, 3.63)
Injury or fall 132 (20.2) 151 (23.2) 103 (15.8) 4.47 (0.30, 8.65) 7.39 (3.10, 11.68)
Overactive bladder symptoms 12 (1.8) 27 (4.1) 12 (1.8) 0.00 (− 1.56, 1.57) 2.30 (0.48, 4.31)
Psychotic symptoms 30 (4.6) 36 (5.5) 20 (3.1) 1.54 (− 0.56, 3.73) 2.46 (0.27, 4.77)
Rash, dermatitis, urticaria 79 (12.1) 66 (10.1) 38 (5.8) 6.30 (3.24, 9.47) 4.30 (1.38, 7.32)
Sleep disturbance 67 (10.3) 55 (8.4) 31 (4.7) 5.53 (2.71, 8.48) 3.69 (1.01, 6.47)
Syncopal like events 26 (4.0) 27 (4.1) 17 (2.6) 1.38 (− 0.58, 3.44) 1.54 (− 0.44, 3.62)